These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12515785)

  • 1. Radical prostatectomy as treatment for prostate cancer.
    Jewett MA; Fleshner N; Klotz LH; Nam RK; Trachtenberg J
    CMAJ; 2003 Jan; 168(1):44-5. PubMed ID: 12515785
    [No Abstract]   [Full Text] [Related]  

  • 2. [A fair trial? The European randomized prostatic cancer study].
    Scholten HJ
    Ned Tijdschr Geneeskd; 1995 Jun; 139(25):1302-3. PubMed ID: 7541896
    [No Abstract]   [Full Text] [Related]  

  • 3. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial.
    Schulz RJ; Kagan AR
    J Natl Cancer Inst; 2009 Jan; 101(2):124. PubMed ID: 19141784
    [No Abstract]   [Full Text] [Related]  

  • 5. Radical prostatectomy or watchful waiting in early prostate cancer?
    Siemens DR
    CMAJ; 2003 Jan; 168(1):67. PubMed ID: 12515790
    [No Abstract]   [Full Text] [Related]  

  • 6. Radical prostatectomy for early prostate cancer improves long term survival.
    Alibhai SM; Gogov S
    Cancer Treat Rev; 2005 Dec; 31(8):640-3. PubMed ID: 16289577
    [No Abstract]   [Full Text] [Related]  

  • 7. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
    Loeb S; Yu X; Nadler RB; Roehl KA; Han M; Hawkins SA; Catalona WJ
    J Urol; 2007 Jan; 177(1):102-6; discussion 106. PubMed ID: 17162013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early versus delayed intervention for prostate cancer: the case for early intervention.
    Loeb S; Catalona WJ
    Nat Clin Pract Urol; 2007 Jul; 4(7):348-9. PubMed ID: 17563779
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment on: Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
    Korfage IJ
    Eur Urol; 2009 Feb; 55(2):432. PubMed ID: 18783875
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population?
    Pfitzenmaier J; Pritsch M; Haferkamp A; Jakobi H; Fritsch F; Gilfrich C; Djakovic N; Buse S; Pahernik S; Hohenfellner M
    BJU Int; 2009 Apr; 103(7):877-82. PubMed ID: 19007372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Partin AW
    J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen adjusted for total prostatic tumor volume as a predictor for outcome after radical prostatectomy.
    Hayashi N; Urashima M; Ikemoto I; Kuruma H; Arai Y; Kuwao S; Baba S; Egawa S
    Prostate Cancer Prostatic Dis; 2007; 10(1):60-5. PubMed ID: 17003775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy.
    Freedland SJ; deGregorio F; Sacoolidge JC; Elshimali YI; Csathy GS; Dorey F; Reiter RE; Aronson WJ
    J Urol; 2003 Apr; 169(4):1325-30. PubMed ID: 12629353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial comment on: Oncological and functional results of antegrade radical retropubic prostatectomy for the treatment of clinically localised prostate cancer.
    van der Poel HG
    Eur Urol; 2008 Mar; 53(3):561-2. PubMed ID: 17683855
    [No Abstract]   [Full Text] [Related]  

  • 17. The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.
    Kositsawat J; Flanigan RC; Meydani M; Choi YK; Freeman VL
    J Urol; 2007 Dec; 178(6):2391-6; discussion 2396. PubMed ID: 17936811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survival benefit from radical prostatectomy for early prostate cancer.
    Ray E; O'Brien T
    Int J Clin Pract; 2005 Oct; 59(10):1122-3. PubMed ID: 16178975
    [No Abstract]   [Full Text] [Related]  

  • 19. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
    Sengupta S; Christensen CM; Zincke H; Slezak JM; Leibovich BC; Bergstralh EJ; Myers RP; Blute ML
    J Urol; 2006 Aug; 176(2):559-63. PubMed ID: 16813889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPCG-4: a needed START to PIVOTal data to promote and protect evidence-based prostate cancer care.
    Wilt TJ
    J Natl Cancer Inst; 2008 Aug; 100(16):1123-5. PubMed ID: 18695131
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.